With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Janeen Madan Keller is a senior policy analyst and assistant director of global health at the Center for Global Development. Since joining CGD in June 2015, her research has covered a range of topics including global health financing and aid effectiveness, among others. Previously, she spent two years in Dakar, Senegal, where she worked with the UN World Food Program supporting nutrition and food security programs across West Africa. She has also worked with UNICEF in Mali and conducted research on health behavior change in Niger. Originally from Mumbai, India, she holds an MS in public health nutrition and food security from Tufts University and a BA with honors in political science and French from Vassar College.
The world will struggle to achieve the goals of ending extreme poverty and hunger by 2030 unless there is a sharp increase in agricultural productivity in Africa. Across sub-Saharan Africa, most people live in rural areas and rely on agriculture for their livelihoods; most of them are poor and many are hungry. Could genetically modified organisms (GMOs) help to address some of the causes contributing to Africa’s lagging agricultural productivity? Our answer is a qualified maybe.
While the misuse of antimicrobials in human health is a key factor accelerating the emergence of drug resistance, we should not overlook the role of agriculture. This paper makes the case for a global treaty to reduce antimicrobial use in livestock.
With the US Congress considering cuts to foreign assistance and aid budgets in other donor countries coming under increased pressure, evidence about what works in global development is more important than ever. Evidence should inform decisions on where to allocate scarce resources—but to do so, evaluations must be of good quality.
Our concluding message to young professionals and young people in general is this: engage with us. Tell us what you think is working in development, what isn’t, and why. You will help advance CGD’s mission to fight poverty through innovative, evidence-based policies by keeping the dialogues we foster energetic, fresh, and as inclusive as possible.
Health products—including drugs, devices, diagnostics, and vector control tools—are essential for meeting the healthcare needs of any population. Right now, many low- and lower-middle-income countries rely on donor-managed mechanisms to procure a large share of these health commodities. But this status quo won’t stay static for long, and the global health community must prepare for sweeping changes in global health and procurement over the next 10–20 years. Here’s some of what we see happening now and on the immediate horizon.
Evaluations are key to learning and accountability yet their usefulness depends on the quality of their evidence and analysis. This brief summarizes the key findings of a CGD Working Paper that assessed the quality of aid agency evaluations in global health. By looking at a representative sample of evaluations—both impact and performance evaluations—from major health funders, the study authors developed 10 recommendations to improve the quality of such evaluations and, consequently, increase their usefulness.
With aid budgets shrinking and even low-income countries increasingly faced with cofinancing requirements, this is the right time for global health funders such as the Global Fund and their donors to formally introduce Health Technology Assessment (HTA), both at the central operations level and at the national or regional level in recipient countries. In this CGD Note, we explain why introducing HTA is a good idea. Specifically, we outline six benefits that the application of HTA could bring to the Global Fund, the countries it supports, and the broader global health community.